Sign in

You're signed outSign in or to get full access.

LT

Larimar Therapeutics, Inc. (LRMR)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 net loss widened to $28.8M and diluted EPS was -$0.45 as R&D spending surged on manufacturing scale-up and lyophilization development . Versus Wall Street, EPS missed consensus (-$0.319) by $0.131, while revenue remained non-existent as expected (consensus $0) *.
  • Regulatory momentum accelerated: FDA indicated openness to skin frataxin (FXN) concentration as a reasonably likely surrogate endpoint to support accelerated approval, aligning with Larimar’s registrational plan .
  • Operational updates: lyophilized drug product accepted by FDA for transition into clinical program mid-2025; Phase 3 remains on track for mid-2025; BLA submission targeted by year-end 2025 .
  • Liquidity remained strong with $183.5M in cash, cash equivalents, and marketable securities at year-end 2024; runway projected into Q2 2026, a refinement from prior “into 2026” .

What Went Well and What Went Wrong

What Went Well

  • FDA engagement: “open to considering the use of skin FXN concentration as a reasonably likely surrogate endpoint” under the START pilot, supporting an accelerated path and aligning with Larimar’s current approach .
  • CMC progress: FDA accepted comparability data to transition the lyophilized product (intended for commercialization) into clinical development in mid-2025, de-risking formulation plans .
  • Clinical execution and near-term catalysts: OLE continues with all participants at 50 mg, and adolescent PK run-in dosing on track to complete by end of March 2025; global Phase 3 to initiate mid-2025 .

What Went Wrong

  • R&D cost spike drove the miss: Q4 R&D rose to $26.7M (+$16.1M YoY), primarily due to $15.0M in manufacturing costs (lyophilization development, production scaling and dose production), lifting the net loss to $28.8M .
  • Safety signal management: Safety team deemed anaphylaxis an adverse drug reaction likely associated with nomlabofusp, prompting premedication for the first month of dosing in OLE to mitigate allergic reactions .
  • EPS miss vs. consensus: Q4 diluted EPS (-$0.45) underperformed Wall Street (-$0.319), reflecting higher operating expenses and manufacturing scale-up timing; other income partially offset but was insufficient to close the gap *.

Financial Results

MetricQ2 2024Q3 2024Q4 2024
Net Loss ($USD Millions)-$21.627 -$15.499 -$28.824
Diluted EPS ($USD)-$0.34 -$0.24 -$0.45
Research & Development ($USD Millions)$19.682 $13.919 $26.738
General & Administrative ($USD Millions)$4.917 $4.345 $4.555
Other Income ($USD Millions)$2.972 $2.765 $2.469
Cash + Marketable Securities ($USD Millions)$226.1 $203.7 $183.5
Revenue vs. EstimatesQ2 2024Q3 2024Q4 2024
Revenue Actual ($USD Millions)— (no revenue reported) — (no revenue reported) — (no revenue reported)
Revenue Consensus Mean ($USD Millions)0.0*0.0*0.0*
EPS vs. EstimatesQ2 2024Q3 2024Q4 2024
Diluted EPS Actual ($USD)-$0.34 -$0.24 -$0.45
Primary EPS Consensus Mean ($USD)-$0.315*-$0.370*-$0.319*
Surprise ($USD)-$0.025*+$0.130*-$0.131*

Values retrieved from S&P Global*.

Notes:

  • No revenue and margins are not applicable for development-stage biotech; operating expense trends and liquidity are principal financial indicators .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
BLA submission to seek accelerated approval2025 timing2H 2025 By year-end 2025 Maintained (refined timing)
Global Phase 3 initiationMid-2025Mid-2025 on track Mid-2025 on track Maintained
OLE 50 mg topline data update2025Mid-2025 initial expectation September 2025 Updated (more specific, later in 2H)
Adolescent PK run-in dosingQ4 2024–Q1 2025Initiate by year-end 2024 Dosing ongoing; completion by end of March 2025 Updated (timeline extension/clarified completion)
Transition to lyophilized productMid-2025Not previously specifiedFDA accepted comparability; introduce mid-2025 New
Cash runwayInto 2026Into 2026 Into Q2 2026 Refined (specific quarter)

Earnings Call Themes & Trends

Note: No Q4 earnings call transcript was available in our document catalog; themes are derived from the 8-K/press release and prior quarterly disclosures .

TopicPrevious Mentions (Q-2, Q2 2024)Previous Mentions (Q-1, Q3 2024)Current Period (Q4 2024)Trend
FDA regulatory pathway (START pilot, RLSE)Selected to START program; aligning CMC with clinical plans Initial FDA START engagement; ILAP designation (U.K.) FDA open to skin FXN as RLSE; focus on skin FXN; additional PD analyses suggested Strengthening regulatory momentum
CMC/formulationManufacturing scale-up costs rising Ongoing scaling and assay development FDA accepted lyophilized product comparability; plan mid-2025 introduction De-risking formulation/commercial readiness
Clinical OLE outcomesOLE sites activated; interim data Q4 OLE interim data mid-Dec planned OLE at 50 mg for all; update on 30–40 pts in Sept 2025 Advancing dose, dataset expanding
Pediatric PK run-inPlan adolescent/children PK run-in by year-end Initiation on track by year-end Adolescents dosing ongoing; completion by end of March 2025 Executing; timeline clarified
Liquidity/runway$226.1M; runway into 2026 $203.7M; runway into 2026 $183.5M; runway into Q2 2026 Strong, but declining as program scales
Safety/tolerabilityPhase 1/2 generally well-tolerated narratives OLE data expected; non-ambulatory inclusion Anaphylaxis likely ADR; premedication introduced for first month Managing emerging risks proactively

Management Commentary

  • “We are enthusiastic about...skin frataxin (FXN) concentrations as a potential novel surrogate endpoint...via our participation in the START pilot program as we further refine our registrational plan” — Carole Ben-Maimon, MD, President & CEO .
  • “Our open label extension (OLE) study continues to advance...all participants are currently receiving the 50 mg dose...We have received feedback from both FDA and EMA...on track to initiate [global Phase 3] mid-2025” — Carole Ben-Maimon, MD .
  • December OLE update: “25 mg...increased and maintained tissue FXN levels over time...early trends towards improvement in clinical outcomes...We are excited to be increasing the dose to 50 mg...” — Carole Ben-Maimon, MD .

Q&A Highlights

  • Q4 earnings call transcript was not available in the document catalog; no transcript could be retrieved despite targeted search. We therefore cannot provide Q&A highlights or any guidance clarifications beyond press release disclosures .

Estimates Context

  • EPS: Q4 actual -$0.45 missed consensus -$0.319 by -$0.131; Q3 actual -$0.24 beat consensus -$0.370 by +$0.130; Q2 actual -$0.34 missed consensus -$0.315 by -$0.025 *.
  • Revenue: Consensus was $0 across Q2–Q4; Larimar reported no revenue, consistent with development-stage status *.
  • Adjustments: Street models should reflect higher near-term OpEx for lyophilization, production scaling, and Phase 3 start-up; regulatory probability of success may be revisited given FDA’s surrogate endpoint openness *.

Values retrieved from S&P Global*.

Key Takeaways for Investors

  • Regulatory pathway de-risking: FDA’s openness to FXN as RLSE and EMA feedback materially improve the probability of an accelerated approval path; BLA targeted by year-end 2025 remains intact .
  • Near-term catalysts: Sept 2025 program update (OLE 50 mg topline; adolescent PK data), mid-2025 Phase 3 initiation, lyophilized product transition mid-2025 — each a potential stock-moving event .
  • Expense trajectory: Elevated R&D (manufacturing/CMC) drove the Q4 EPS miss; expect continued high OpEx through Phase 3 start-up and lyophilized product integration .
  • Safety management: Anaphylaxis risk identified; protocol amended for premedication. Watch for safety dataset adequacy discussions with FDA as a gating factor for BLA .
  • Liquidity: $183.5M with runway into Q2 2026 supports execution through Phase 3 initiation and BLA submission; dilution risk lower near term but monitoring is warranted as development expands .
  • Trading lens: Headlines on FDA regulatory interactions (RLSE), CMC/formulation acceptance, and OLE 50 mg efficacy signals likely drive sentiment; EPS variances are secondary vs. clinical/regulatory catalysts in this name .
  • Medium-term thesis: First potential disease-modifying therapy in FA with protein replacement differentiation; regulatory momentum plus clinical biomarker improvements (FXN, gene/lipid profiles) support value inflection into late-2025 .